image: Sphingosine-1-phosphate receptors are the targets for treating many human diseases and selectivity is one of the major hindrances during drug development. Two crystal structures of human sphingosine-1-phosphate receptor 3 in complex with one bitopic ligand SPM-242 as well as allosteric ligands Cpd-32 or CYM52581 bound simultaneously was reported, and together with cryo-electron microscopy structures of S1P2 and S1P3 in complex with heterotrimeric Gi protein, the activation process of Sphingosine-1-phosphate receptors is revealed and the key sites for designation of better selective S1P ligands are proposed.
Credit: HIGHER EDUCATION PRESS
Background
Sphingosine-1-phosphate receptors (S1P1-S1P5) are critical regulators of cell survival, migration, and inflammation, making them attractive therapeutic targets for conditions including cancer, fibrosis, and cardiovascular diseases . S1P3 receptors suppress tumor angiogenesis and bone loss, while S1P1 drives metastasis and disrupts blood-tumor barriers . Despite their therapeutic potential, developing selective ligands has been challenging due to limited understanding of their binding mechanisms. Allosteric ligands offer advantages such as subtype selectivity and biased signaling, but their discovery for GPCRs remains difficult . This research aimed to elucidate the structural basis of ligand binding to facilitate rational drug design.
Methodology: Structural Determination
Researchers employed advanced structural biology techniques to visualize ligand-receptor interactions at atomic resolution. They determined crystal structures of human S1P3 in complex with the bitopic ligand SPM-242 and allosteric antagonists Cpd-32 and CYM52581 . Additionally, cryo-electron microscopy (cryo-EM) structures of S1P2 and S1P3 bound to heterotrimeric Gi protein were solved to understand inhibition mechanisms and subtype selectivity . These structural studies were complemented by extensive functional assays and site-directed mutagenesis to validate binding interactions and assess their functional consequences .
Key Findings: Allosteric and Bitopic Binding Sites
The research revealed unprecedented insights into S1P receptor pharmacology. SPM-242, a bitopic antagonist, simultaneously occupies both the orthosteric pocket (where endogenous S1P binds) and a distinct allosteric pocket, with its zwitterionic head group mimicking S1P's phosphate and amine groups . Remarkably, S1P3 possesses an allosteric binding site outside the helical bundle—a novel feature for class A GPCRs—where structurally distinct antagonists Cpd-32 and CYM52581 bind to a lipid-facing pocket formed by helices II-IV . Both allosteric ligands form critical hydrogen bonds with residue S117, stabilizing the receptor in an inactive conformation . The simultaneous binding of bitopic and allosteric ligands produces synergistic inhibition, significantly enhancing receptor stability . High sequence variation in the allosteric pocket explains subtype selectivity, with specific residues determining ligand preference for S1P3 over S1P1.
Significance for Drug Design
These structural insights provide a comprehensive framework for rational drug design targeting S1P receptors. The identification of distinct allosteric and bitopic binding sites, along with selectivity determinants, enables structure-based optimization of selective antagonists. The high sequence variation in allosteric pockets offers opportunities for designing receptor-specific ligands, potentially overcoming limitations of current non-selective compounds . This work advances understanding of GPCR pharmacology and facilitates development of precision therapeutics for cancer, inflammation, and cardiovascular diseases.
Journal
Protein & Cell
Method of Research
Experimental study
Subject of Research
Not applicable
Article Title
Structural basis of allosteric and bitopic ligands binding in sphingosine-1-phosphate receptors 2 and 3
Article Publication Date
20-Aug-2025